| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-07-22 | NCT07720310 Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus | Enrolling by Invitation |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in… | Ovarian Cancer | Recruiting |
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point… | Metastatic Cervical Cancer | Recruiting |
| Not specified | |||
| NCT07308990 | Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients… | Prostate Cancer Patients Undergoing Radical Prostatectomy | Recruiting |
| NCT07524816 | Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory… | Large B-Cell Lymphoma (LBCL) | Recruiting |
| NCT07720310 | Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus | System Lupus Erythematosus(SLE) | Enrolling by Invitation |